Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections

June 29, 2021 10:00 UTC Leading institutional and strategic investors commit $75 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Gilead Sciences, RA Capital Management and Frazier Life Sciences CARLSBAD, Calif. & LARKSPUR, Calif.--(BUSINESS WIRE)-- , Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement. Upon closing of the transaction, the company will be renamed “Pardes Biosciences, Inc.” (Combined Company) and will be led by Uri A. Lopatin, M.D., Chief Executive Officer of Pardes. The Combined Company’s common stock is expected to be listed on NASDAQ under the ticker symbol PRDS.
（以上内容由医药魔方AI生成）